Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Royal Alexandra Hospital
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00375869CT.gov Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Traumatic Brain Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Darbepoetin (this asset) | Royal Alexandra Hospital | P2 | CCC · 50 |
| Apsolol | Tanta University | P4 | BBB |
| Amantadine | SHINKEI Therapeutics, Inc | P4 | BB |
| Melatonin | Children's National Research Institute | P4 | BB |
| Dexmedetomidine | Universitas Jenderal Soedirman | P4 | BB |
| Serostim | Anhui Provincial Hospital | P4 | BB |
| Valproic Acid | Northwestern University | P4 | BB |
| Nepenthe | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Lacto-Flavin | POLYSAN Scientific & Technological Pharmaceutical Company | P3 | BB |
+42 more in the Traumatic Brain Injury cohort
Other indications for Darbepoetin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anemia | — | P3 | BB · 64 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | CCC · 53 |
| Prostate Cancer | — | P2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Darbepoetin in Traumatic Brain Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/darbepoetin-traumatic-brain-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →